General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-20 | 2024-03 | -3.33 | -9.14 | -5.81 | -174.47% |
2024-04-02 | 2023-12 | -17.14 | N/A | N/A | N/A |
2023-11-14 | 2023-09 | -5.99 | -48.77 | -42.78 | -714.19% |
2023-08-14 | 2023-06 | -115.6 | -36.8 | 78.8 | 68.17% |
2023-04-03 | 2022-12 | -1.48 | N/A | N/A | N/A |
2022-11-14 | 2022-09 | -100 | -210.8 | -110.8 | -110.80% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-07-18 | ALBANNA AMRO A | Officer | 1.00 | Purchase |
2021-06-03 | ALBANNA ROWENA | Chief Operating Officer | 0.00 | Stock Award(Grant) |
2023-09-06 | BNP PARIBAS SECURITIES CORPORATION NORTH AMERICA | Unknown | 22.34K | Sale |
2021-05-25 | FARLEY THOMAS J | Officer | 2.50K | Purchase |
2020-07-21 | KIAIE NAMVAR | Director | 2.22K | Conversion of Exercise of derivative security |
2021-06-03 | PANKOVCIN CORINNE D | Chief Financial Officer | 169.22K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Sabby Management, LLC | 14.74K | 265.30K | 6.17% |
2023-06-29 | Vanguard Group Inc | 1.16K | 20.92K | 0.49% |
2023-09-29 | IFP Advisors, Inc | 1.08K | 13.53K | 0.45% |
2023-06-29 | State Street Corporation | 948.00 | 17.06K | 0.40% |
2023-06-29 | Natixis | 250.00 | 4.50K | 0.10% |
2023-06-29 | Tower Research Capital LLC (TRC) | 246.00 | 4.43K | 0.10% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 1.16K | 20.92K | 0.49% |
2023-05-30 | Fidelity Extended Market Index Fund | 39.00 | 951.00 | 0.02% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 44.00 | 1.07K | 0.02% |
2023-05-30 | Fidelity Series Total Market Index Fund | 18.00 | 439.00 | 0.01% |
Split | Date |
---|---|
1 : 40 | 2023-08-18 |
1 : 50 | 2022-09-14 |
1 : 50 | 2022-09-12 |
Another RS?
Nothing avaiable yet. People here love gossip.
David, wtf is this? here is not a forum to discuss cripto. Go to Coinbase.
The senior management has been burning cash and not cutting expenses. Besides of that, there is a lack of information, no transparency at all. shame
Company got a bridge loan from a shark. Even today, we don’t know the net income from Cellvera. Don’t you remember the overdue of usd14MM ?
This company has a very poor or bad faith management .
Buyout confirmed??? LOL
Thomas pickens you are back!
Where is the SEC???
No news yet? about the shareholders meeting and public offering.
Let’s wait a law firm like Kuznick Law PLLC to open again an new investigation. The CEO and his management ate the responsible for the destruction of this company. H.C is the only research company which gave buy recommendation on 11/14/22. Now it is responsible to sell stocks to a public. A good example of conflict of interests. A big mess and a true and pure POS.
How is possible to atract new capital? Really weird.
How is possible to be so incompetent? or is a bad faith?
I tried to find a report from H.C. Wainwright about this company, I want to understandwhat are the fundamentals to the recommendation of USD4. This reminds me another (the sole) guy from Dawson, who has disappeard after a deal with ADITX. The 10Q is really complex without a detailed information about Cellvera’s deafault and the nain shareholders. If somebody here knows, please, share them with us.
Finally Amro did something good. We need more good news. Who was the investor who put USD20MM?
Wow, the second it gets above $4 that push it back down. Dark pool volume must be massive. Keep pushing everyone, we will squeeze them
Everyone buy a few more at the ask and we will launch! I’m in for another 100
Everyone slap the ask, we get this over $4 and it will fly!!! They are trapped